Development & Clinical Application of K-PaC Registry Version 2.0
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Pancreatic Cancer. Basic parameters: from 19 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- South Korea
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Development and clinical use of pancreatic cancer registry * Development of K-PaC Registry v.2.0: Retrospective data integration from 2010 to 2022 and prospective data collection from more than 811 enrolled patients from 2023 to 2029 * Creation of clinical evidence (RWE) based on pancreatic cancer real-world data (RWD): 3 or more
Detailed description
We plan to collect retrospective and prospective data based on medical data centered on EMR. ∙ This registry is built on EMR data containing specific information on medical provider records and patient health records. It is designed to enable the confirmation of specific treatment history and medical staff records, and to generate highly valid RWD-based evidence through EMR information such as accurate diagnosis of disease, treatment method, symptom changes, monitoring of lab data values, and patient status. ∙ Based on the built registry data, it is possible to conduct research based on evaluation of drug treatment and additional comparison of indications for elderly or poor general condition patients who are excluded from regular clinical trials, as well as research on diagnosis and prognosis. The clinical information and biomarkers of the prospective patient group are analyzed to evaluate the correlation with treatment response, overall and progression-free survival rates.
Primary outcome measures
- Development and clinical use of a pancreatic cancer registry [Time frame: From initial diagnosis to death]
Secondary outcome measures (1)
- Assessing the association between pancreatic cancer biomarker markers and treatment response, overall and progression-free survival [Time frame: From initial diagnosis to death]
Eligibility criteria
Inclusion criteria
- Clinical diagnosis of pancreatic cancer
Exclusion criteria
- In cases where medical record review is not feasible
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
South Korea · 1 center
- National Cancer Center — Goyang
Identifiers
NCT: NCT07171515 · NCC2022-0061